ArticleFrontiers in endocrinology2025
An impact of type 2 diabetes mellitus on NKT-like cell population in humans: a new insight into impaired immune response in hyperglycemia.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pathophysiological mechanisms and clinical management of type 2 diabetes mellitus complicated with anal fistula.Frontiers in surgery · 2026Review
- Significance of innate immune surveillance in emphysematous pancreatitis.Frontiers in immunology · 2026Review
- Vitamin D May Increase the Number of CD4-CD8+ NKT-like Cells in Humans-A Novel Insight into Potential Immunomodulatory Action.Nutrients · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by insulin resistance and pancreatic β-cell dysfunction. T2DM is associated with increased risk of infections and of several malignancies, although the underlying immune mechanisms remain not fully elucidated. Natural Killer T-like cells (NKT-like) belong to a unique subpopulation of T lymphocytes defined by expression of the markers specific to NK (Natural Killer) cells (CD56) and T cells (TCR - T cell receptor). As NKT-like cells possess unique cytotoxic properties, they form a bridge between innate and adaptive immunity. The aim of our study was to assess associations between the presence of T2DM and the profile of NKT-like cell subpopulations. Methods: Peripheral blood mononuclear cells (PBMCs) were obtained from 86 patients. NKT-like cells were subsequently isolated from the PBMC fraction using a CD3+ CD56+ NKT cell isolation kit in combination with magnetic bead-based separation. To evaluate NKT-like cells subpopulations distribution, flow cytometry (FC) was used. NKT-like cells were categorized into CD4-CD8- (double negative, DN), CD4+CD8-, CD4-CD8+, and CD4+CD8+ (double positive, DP) subpopulations, with further subdivision of DP and CD4-CD8+ subpopulations into CD4highCD8mid/CD4midCD8high and CD4-CD8mid/CD4-CD8high subpopulations, respectively. Associations between NKT-like cells subpopulation and T2DM, and - additionally - correlations between NKT-like and glucose levels and body mass index (BMI) were evaluated. Results: T2DM group demonstrated a significantly diminished percentage of DN NKT-like cells as compared to control group. A strong negative correlation was observed between DN NKT-like cell levels and glucose concentration, but not BMI. Based on further subdivision of DP and CD4-CD8+ subpopulations a significant negative correlation was also observed between glucose levels and the CD4 Conclusions: Our study demonstrated that DN NKT-like cells, which possess significant cytotoxic activity, are depleted in T2DM patients. These results may explain the novel potential mechanism of increasing susceptibility to infections and cancers in T2DM and emphasize the need for precise glycemic control. The novel insights into NKT-like cell immunomodulation role in T2DM may open new, targeted therapies in metabolic diseases. Further research in larger cohorts is needed to confirm these pioneering observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.